『医世象』新辅助化疗方案：胃癌患者中位生存期高达50个月！( 二 )

所以，对于局部晚期可切除食管-胃结合部腺癌采用新辅助方案化疗，与ECF/ECX方案相比， FLOT提高了患者的总生存期。
参考文献
1.Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N.Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.Lancet Oncol. 2016 Dec;17(12):1697-1708.
【『医世象』新辅助化疗方案：胃癌患者中位生存期高达50个月！】2.Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM.Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.Lancet. 2019 May 11;393(10184):1948-1957.